OBJECTIVE： To investigate the effects of atorvastatin with different doses on related indicators and major adverse cardiovascular events （MACE） in patients with acute myocardial infarction （AMI） after percutaneous coronary intervention （PCI）. METHODS： 120 patients with AMI after PCI were randomly divided into conventional dose group （60 cases） and high dose group（60 cases）. All patients were immediately given low molecular weight heparin， Aspirin enteric-coated tablet， Clopidogrel bisulfate tablet， Angiotensin-converting enzyme inhibitor， β-blockers， nitrates and other conventional treatment； based on it， conventional dose group was given 20 mg Atorvastatin calcium tablet， once every day before bedtime； high dose group was given 40 mg Atorvastatin calcium tablet， once every day before bedtime. The treatment course for both groups was 1 month. Total cholesterol （TC）， triglyceride （TG）， low density lipoprotein cholesterol （LDL-C）， high density lipoprotein cholesterol （HDL-C）， C-reactive protein （CRP）， OX40L， interleukin （IL）-6 levels in 2 groups before and after treatment were observed， the correlation among OX40L with CRP and IL-6 were analyzed， and the incidence of MACE in 2 groups was recorded after 1 month follow-up. RESULTS： Before treatment， there were no significant differences in the TG， TC， LDL-C， HDL-C， OX40L， CRP and IL-6 between 2 groups （P＞0.05）. After treatment， TG， TC， LDL-C， OX40L， CRP and IL-6 were aignificantly lower than before， TC， LDL-C， OX40L， CRP and IL-6 in high dose group were lower than conventional dose group， HDL-C was significantly higher than before， the differences were statistically significant （P＜0.01 or P＜0.05）； but there was no significant difference in the HDL-C between 2 groups （P＞0.05）. Before treatment， OX40L showed positive correlation with CRP （r＝0.746， P＜0.01） and IL-6 （r＝0.763， P＜0.01）； after treatment， OX40L also showed positive correlation with CRP （r＝0.755， P＜0.01） and IL-6 （r＝0.760， P＜0.01）. The incidence of MACE in high dose group were significantly lower than conventional dose group， the difference was statistically significant（P＜0.05）. CONCLUSIONS： Based on the conventional treatment， atorvastatin can significantly reduce lipid， inflammation levels and incidence of MACE， but the effect is more significant in high dose.